期刊
METHODS
卷 36, 期 1, 页码 11-24出版社
ACADEMIC PRESS INC ELSEVIER SCIENCE
DOI: 10.1016/j.ymeth.2005.01.002
关键词
therapeutic antibodies; antibody engineering; affinity maturation; effector functions; FcRn binding; antibody fragments; immunoconjugates; immunotoxins; immunocytokines; ADEPT; radio-labeled antibodies; Bi-specific antibodies; PEGylation
Therapeutic antibodies represent one of the fastest growing areas of the pharmaceutical industry. There are currently 18 monoclonal antibodies in the market that have been approved by the FDA and over 150 in clinical developments. Driven by innovation and technological developments, scientists have gone beyond the traditional antibody molecules. Antibodies have been engineered in a variety of ways to meet the challenges posed by different biological settings. Described in this review is an abridged account of the different ways antibodies have been tailored to make them efficient drug molecules. (c) 2005 Elsevier Inc. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据